Illumina (ILMN) Scheduled to Post Quarterly Earnings on Thursday

Illumina (NASDAQ:ILMNGet Rating) is scheduled to issue its quarterly earnings data after the market closes on Thursday, August 11th. Analysts expect the company to announce earnings of $0.63 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Illumina (NASDAQ:ILMNGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The life sciences company reported $1.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.20. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.22 billion. Illumina had a net margin of 15.04% and a return on equity of 8.37%. Illumina’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company posted $1.89 earnings per share. On average, analysts expect Illumina to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Illumina Stock Up 1.8 %

Shares of NASDAQ ILMN opened at $223.10 on Thursday. The stock has a market cap of $35.05 billion, a PE ratio of 48.50, a PEG ratio of 1.69 and a beta of 1.15. The business has a fifty day moving average of $205.25 and a two-hundred day moving average of $281.64. Illumina has a 52-week low of $173.45 and a 52-week high of $526.00. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.54 and a current ratio of 1.85.

Insider Activity at Illumina

In other Illumina news, SVP Susan H. Tousi sold 250 shares of the company’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $214.85, for a total value of $53,712.50. Following the transaction, the senior vice president now directly owns 41,833 shares of the company’s stock, valued at approximately $8,987,820.05. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, SVP Susan H. Tousi sold 250 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $214.85, for a total transaction of $53,712.50. Following the sale, the senior vice president now directly owns 41,833 shares of the company’s stock, valued at approximately $8,987,820.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Alexander Aravanis sold 539 shares of the stock in a transaction on Thursday, July 7th. The stock was sold at an average price of $200.00, for a total value of $107,800.00. Following the sale, the senior vice president now directly owns 3,346 shares in the company, valued at $669,200. The disclosure for this sale can be found here. 0.13% of the stock is owned by company insiders.

Institutional Trading of Illumina

Large investors have recently bought and sold shares of the business. Brown Brothers Harriman & Co. boosted its stake in Illumina by 460.9% in the first quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock valued at $45,000 after buying an additional 106 shares in the last quarter. Penserra Capital Management LLC acquired a new position in shares of Illumina in the first quarter valued at approximately $64,000. Geneos Wealth Management Inc. increased its position in Illumina by 28.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 270 shares of the life sciences company’s stock valued at $94,000 after acquiring an additional 60 shares during the period. Mather Group LLC. bought a new position in shares of Illumina during the first quarter valued at $204,000. Finally, Ergoteles LLC acquired a new position in shares of Illumina during the first quarter worth $234,000. 86.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Citigroup dropped their price objective on Illumina from $325.00 to $220.00 and set a “neutral” rating for the company in a report on Friday, July 8th. Cowen set a $412.00 price objective on Illumina in a research report on Tuesday, July 19th. Piper Sandler decreased their price objective on Illumina from $460.00 to $360.00 and set a “na” rating for the company in a research report on Sunday, May 15th. Barclays lowered Illumina from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $350.00 to $150.00 in a research report on Wednesday, July 13th. Finally, Cowen cut their target price on Illumina from $506.00 to $492.00 in a research note on Friday, May 6th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $398.67.

Illumina Company Profile

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Featured Stories

Earnings History for Illumina (NASDAQ:ILMN)

Want More Great Investing Ideas?

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.